This systematic review with meta-analysis examines the rates of cardiovascular adverse events among patients receiving carfilzomib for the treatment of multiple myeloma.
from Cancer via ola Kala on Inoreader http://ift.tt/2CiBVgE
via IFTTT
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου